Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 2/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.48 |
| ▸ | TIPARP | Q7Z3E1 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 6/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31014094 | 1.00 | DDB1 (0.48) | DDB1CRBNTIPARPNAMPTMAPK1 | |
| SCHEMBL30368078 | 1.00 | DDB1 (0.48) | DDB1CRBNTIPARPNAMPTMAPK1 | |
| SCHEMBL31013893 | 1.00 | DDB1 (0.48) | DDB1CRBNTIPARPNAMPTMAPK1 | |
| SCHEMBL30368217 | 0.91 | DDB1 (0.48) | DDB1CRBNTIPARPNAMPTMAPK1 | |
| SCHEMBL25669152 | 0.91 | DDB1 (0.48) | DDB1CRBNTIPARPNAMPTMAPK1 | |
| SCHEMBL24913832 | 0.91 | ESR2 (0.43) | DDB1CRBNTIPARPNAMPTMAPK1 | |
| SCHEMBL24913992 | 0.91 | ESR2 (0.43) | DDB1CRBNTIPARPNAMPTMAPK1 | |
| SCHEMBL30156528 | 0.91 | UCHL1 (0.47) | DDB1CRBNTIPARPNAMPTMAPK1 | |
| SCHEMBL24914056 | 0.91 | ESR2 (0.43) | DDB1CRBNTIPARPNAMPTMAPK1 | |
| SCHEMBL24914221 | 0.91 | UCHL1 (0.47) | DDB1CRBNTIPARPNAMPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117693507-A | Inhibitor compounds | 奈奥芬莱有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-06-15 | — | — | US | disclosed |
| CN-115996907-A | Inhibitors of MLH1 and/or PMS2 for cancer treatment | 奈奥芬莱有限公司 | 2023-04-21 | — | — | CN | disclosed |
| WO-2023002165-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | MSH2, PMS2, MSH6 | DDB1 44/4885CRBN 663/4885TIPARP 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.